Topic Name

Message

If ARUP Consult does not answer your test selection and interpretation questions, or if you would like to suggest ways to improve content or usability, please send a message to the Consult editorial staff.

Please do not include any patient-specific or personal health information (PHI) in your message.

Email Address

An email address is not required, but providing one allows the ARUP Consult editorial staff to respond directly. ARUP will only use your email address to respond to your feedback. See the ARUP privacy policy for more information regarding email use.

CAPTCHA

What code is in the image?

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

AASLD - high efficacy of glecaprevir/pibrentasvir in patients

The American Association for the Study of Liver Diseases: The Liver Meeting. High efficacy of glecaprevir/pibrentasvir in patients with chronic HCV GT1 infection who failed prior treatment with NS5A-inhibitor plus sofosbuvir regimens. Published Nov 2018; accessed Oct 2025.

AASLD - high efficacy of glecaprevir/pibrentasvir in patients

What links here

About

Testing

Education Center

Contact Us

Feedback

AASLD - high efficacy of glecaprevir/pibrentasvir in patients

What links here